Facilitating Access to Approved Medication

Obinutuzumab Injection 1000 mg
Obinutuzumab injection is used with chlorambucil (Leukeran) to treat chronic lymphocytic leukemia (CLL; a type of cancer of the white blood cells).

Get Access To Obinutuzumab Injection 1000 mg

Get The Best Access Price
WhatsApp
Obinutuzumab Injection was approved for medical use in the United States in 2017. It is on the World Health Organization’s List of Essential Medicines.
Obinutuzumab Injection Available Price In India UK Saudi Arabia

Obinutuzumab Injection

  • API – Obinutuzumab
  • Packaging – Glass Bottle
  • Strength – 1000 mg
  • Brand name Available – On Request

What is Obinutuzumab Injection used for?

Obinutuzumab Injection is used with chlorambucil (Leukeran) to treat chronic lymphocytic leukemia (CLL; a type of cancer of the white blood cells).

    Get The Best Access Price
    Disclaimer

    All Trademarks and Brands that appear on website belong to their respective owners and Ikris Pharma Network does not lay and claim on them we only provide Information. We are NOT ONLINE store and We do not sell Narcotics and Sedatives. Iron Sucrose is a pharmaceutical drug that legally requires a medical prescription to be dispensed. Following Information meant for Wholesalers, Suppliers, Exporters, Doctors, Comparator Supplies, Hospitals, Generic, Brand, Corporate Sourcing, reseller, and Pharmacies.

    Get Access To Obinutuzumab Injection 1000 mg

    Shreyaansh Lifesciences, Jaipur. India

    Shreyaansh Lifesciences is registered in Jaipur, India. Registration Number : 08AEEFS9350K1ZI under GST Act. 
    Branch Offices in India : Jaipur | New Delhi

    SF-72-73 2ND FLOOR, Jaipur Electronic Market, Ridhi Sidhi Choraha, Jaipur, Rajasthan, 302018.

    +91 99292 77766

    info@treatmentoptions4u.com
    urgent@treatmentoptions4u.com

    Facts of Medicines

    Obinutuzumab Injection 1000 mg

    HOW SUPPLIED/STORAGE AND HANDLING:

    Obinutuzumab Injection must be refrigerated at 2°C to 8°C (36°F to 46°F). Do not use the Obinutuzumab Injection beyond the expiration date located on the carton and the vial.X.

    DOSAGE

    • Dilute and administer as intravenous infusion. Do not administer as an intravenous push or bolus.
    • The dose for chronic lymphocytic leukemia is 100 mg on day 1 and 900 mg on day 2 of Cycle 1, 1000 mg on day 8 and 15 of Cycle 1, and 1000 mg on day 1 of Cycles 2–6.
    • The dose for follicular lymphoma is 1000 mg on day 1, 8 and 15 of Cycle 1, 1000 mg on day 1 of Cycles 2-6 or Cycles 2-8, and then 1000 mg every 2 months for up to 2 years.
    • 1000 mg/40 mL (25 mg/mL) single-dose vial

    SIDE EFFECTS

    The following clinically significant adverse reactions can occur with Obinutuzumab Injection: Cardiovascular Toxicity, Myelosuppression, Hypersensitivity, Hypertension, Pancreatic Toxicity..

    WARNINGS AND PRECAUTIONS

    • Genetic testing should be indicated in order to detect whether a person is at higher risk of developing hypersensitivity.
    • Obinutuzumab Injection may not be added as a single agent when antiretroviral regimens are changed because of loss of the virologic response.
    • Patients with liver disease should be watchful and cautious in order to Obinutuzumab Injection because it can aggravate the condition.
    • In patients with Obinutuzumab Injection, conditions like immune reconstitution inflammatory syndrome, a change in body fat as well as an increased risk of heart attack may occur.
    • Obinutuzumab Injection is not recommended for use in infants who are under 3 months of age.
    • Cases like lactic acidosis and severe hepatomegaly with steatosis occurred with the use of nucleoside analogues.
    • Sometimes serious hypersensitivity reactions have been associated with Obinutuzumab Injection.

    FAQs – Medicine Questions

    Obinutuzumab Injection 1000 mg
    How long does obinutuzumab infusion take?
    Administer at 25 mg/hr over 4 hours. Do not increase the infusion rate.
    Is obinutuzumab a chemotherapy?
    Obinutuzumab is an anti-cancer (“antineoplastic” or “cytotoxic”) chemotherapy drug. Obinutuzumab is classified as a “monoclonal antibody” (For more detail, see “How Obinutuzumab Works” section below).
    How often is obinutuzumab given?
    GAZYVA is given for a total of 6 cycles, or rounds of treatment. Each cycle will last 28 days. Treatment occurs only on certain days of each cycle and that is usually followed by several weeks of rest and recovery. This means that most people will complete their GAZYVA treatment in about 6 months.
    Where can I buy Obinutuzumab Injection?

    You can buy Obinutuzumab Injection from any authorized whole-seller after getting a prescription from a qualified doctor. It is always better to check the credential of the whole-seller/supplier/exporter before buying the product.

    The buyer should check the existing law in their home country before importing the product.

    What is the procedure to buy Obinutuzumab Injection?

    Patients can simply fill the order form or can send mail at info@treatmentoptions4u.com. Patients can also send WhatsApp messages to +91 99292 77766 / 98738 10020   We will reply ASAP with the details of theObinutuzumab Injection price as well as procurement procedure.

    Note:- The order will be confirmed only after the receipt of the Valid prescription of the Clinician.

    Is obinutuzumab safe?
    Patients without or with prior treatment in the obinutuzumab plus FC arm demonstrated the highest 4-year overall survival at 94% and 70%, respectively, followed by 85% and 68% in the obinutuzumab plus bendamustine arm, 83% and 59% in the monotherapy arm, and 67% and 54% in the obinutuzumab plus chlorambucil arm.

    NEWS / UPDATES

    1. Roche Products Limited, Electronic medicines compendium (emc), [Revised on Jan 2021] [ Accessed on 11th August 2021], https://www.medicines.org.uk/emc/files/pil.3279.pdf
    2. Genentech, Inc, US Food and Drug Administration, [Revised on Nov 2017] [ Accessed on 9th August 2021], https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125486s017s018lbl.pdf
    3. Jenny O’Nions, William Townsend et al; The role of obinutuzumab in the management of follicular lymphoma; Future Oncology; Published on Nov 2019; Accessed on 11/08/2021; https://pubmed.ncbi.nlm.nih.gov/31538821/